Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment

MLA

Diem, Stefan, et al. “Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment.” Journal of Immunotherapy, no. Preprints, Jan. 2024. EBSCOhost, https://doi.org/10.1097/CJI.0000000000000255.

APA

Diem, S., Fässler, M., Bomze, D., Ali, O. H., Berner, F., Niederer, R., Hillmann, D., Mangana, J., Levesque, M. P., Dummer, R., Risch, L., Recher, M., Risch, M., & Flatz, L. (2024). Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. Journal of Immunotherapy, Preprints. https://doi.org/10.1097/CJI.0000000000000255

Chicago

Diem, Stefan, Mirjam Fässler, David Bomze, Omar Hasan Ali, Fiamma Berner, Rebekka Niederer, Dorothea Hillmann, et al. 2024. “Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment.” Journal of Immunotherapy, no. Preprints (January). doi:10.1097/CJI.0000000000000255.